The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF) DOI Creative Commons

Darshan Hullon,

Ghasaq K. Subeh,

Yu.V. Volkova

et al.

Cardiovascular Diabetology, Journal Year: 2025, Volume and Issue: 24(1)

Published: Feb. 7, 2025

Heart failure with preserved ejection fraction (HFpEF) is a prevalent and complex condition limited effective treatments. Endothelial dysfunction significant component of HFpEF pathophysiology, glucagon-like peptide-1 receptor (GLP-1R) agonists have shown potential benefits in improving endothelial function. This study aims to explore the relationship between mechanisms action GLP-1R agonists, highlighting their therapeutic benefits. A comprehensive review literature was conducted examine etiology HFpEF, role dysfunction, effects on function heart outcomes. The findings indicate that associated various comorbidities, such as obesity, diabetes mellitus, hypertension, which contribute dysfunction. including semaglutide liraglutide, demonstrated cardioprotective effects, vascular function, reducing inflammation, preventing atherosclerosis. Clinical trials, STEP-HFpEF trial, positive results symptoms physical restrictions patients. present promising option for by targeting other pathophysiological mechanisms. Further research needed elucidate precise through exert establish long-term safety efficacy diverse populations.

Language: Английский

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF) DOI Creative Commons

Darshan Hullon,

Ghasaq K. Subeh,

Yu.V. Volkova

et al.

Cardiovascular Diabetology, Journal Year: 2025, Volume and Issue: 24(1)

Published: Feb. 7, 2025

Heart failure with preserved ejection fraction (HFpEF) is a prevalent and complex condition limited effective treatments. Endothelial dysfunction significant component of HFpEF pathophysiology, glucagon-like peptide-1 receptor (GLP-1R) agonists have shown potential benefits in improving endothelial function. This study aims to explore the relationship between mechanisms action GLP-1R agonists, highlighting their therapeutic benefits. A comprehensive review literature was conducted examine etiology HFpEF, role dysfunction, effects on function heart outcomes. The findings indicate that associated various comorbidities, such as obesity, diabetes mellitus, hypertension, which contribute dysfunction. including semaglutide liraglutide, demonstrated cardioprotective effects, vascular function, reducing inflammation, preventing atherosclerosis. Clinical trials, STEP-HFpEF trial, positive results symptoms physical restrictions patients. present promising option for by targeting other pathophysiological mechanisms. Further research needed elucidate precise through exert establish long-term safety efficacy diverse populations.

Language: Английский

Citations

2